MTOR and venous thromboembolism: It aids in preventing venous thromboembolism, particularly in patients aged between 40 and 70 years, by inhibiting the mTOR cell pathway, suppressing platelet aggregation, and modulating immune responses, thereby reducing inflammatory markers such as TNF-alpha and IL-6.